Pharmacogenomics IND EXEMPT SNP Clinical Study - Alectinib and Single Nucleotide Polymorphisms
Status:
Not yet recruiting
Trial end date:
2024-12-28
Target enrollment:
Participant gender:
Summary
Explore the relationship between drug target ALK gene single nucleotide polymorphisms and
ALECENSA - Alectinib therapeutic-effects in patients with non-small cell lung cancer, based
on Oxford precisely sequencing drug targets' genes.
Explore the relationship between drug target CYP4503A4 gene single nucleotide polymorphisms
and ALECENSA - Alectinib side-effects in patients with non-small cell lung cancer, based on
Oxford precisely sequencing drug targets' genes.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair